The Essential Dos and Don'ts in Money Making :
This blog strives to provide CRITICAL INSIGHTS and knowledge on wealth creation.
Since no effort is free of mistakes, or,can be fool proof, the primary condition, always, is - that Reader must take total responsibility on himself for investments or other use he makes of info on this blog by making sure of the info from other sources too.
The blog will remain receptive to any corrections, comments, suggestions etc from readers.
Saturday, February 9, 2013
Apollo Hospitals Enterprise Ltd - Results for Q3 FY 2012-13 - Q.E. DEC,2012 -
Hospitals Enterprise Ltd
Dr.Pratap. C.Reddy, Chairman
Dr.Preetha Reddy, MD
Results for Q3 FY
Stand Alone Results
Apollo Hospitals Enterprise Ltdhas
declared its results for the third quarter ended Dec, 2012.
Net Salesfor Q3 FY 13 stands at Rs.855.79 Cr; compared
to Rs.836.32 Cr inQ2 FY 13 (+ 2.33%);
and Rs.714.75 Cr In Q3 FY 12 (+19.73%).
Total Expenditure for Q3 FY 13 stands at Rs.736.94
Cr; compared to Rs.719.32 Cr inQ2 FY 13
(+2.45%); and Rs.620.63 Cr In Q3 FY 12 (+18.74%).
Profit before Interest, Dep. & Taxesfor Q3 FY 13 stands at Rs.118.85 Cr; compared
to Rs.117.00 Cr inQ2 FY 13 (+1.58%);
and Rs.94.12 Cr In Q3 FY 12 (+26.27%).
Cost of materialsfor Q3 FY 13 stands at Rs.260.62 Cr; compared
to Rs.213.38 Cr inQ2 FY 13 (+22.14%);
and Rs.186.93 Cr In Q3 FY 12 (+39.42%).
Purchases of S-I-Tfor
Q3 FY 13 stands at Rs.222.23 Cr; compared to Rs.225.50 Cr inQ2 FY 13 (-1.45%); and Rs.185.49 Cr In Q3 FY
Employee benefits for Q3 FY 13 stands at Rs.135.75 Cr;
compared to Rs.130.49 Cr inQ2 FY 13
(+4.03%); and Rs.108.60 Cr In Q3 FY 12 (+25%).
Depreciation expense for Q3 FY 13 stands at Rs.27.55Cr; compared to Rs.26.99 Cr inQ2 FY 13 (+2.07%); and Rs.24.25 Cr In Q3 FY
Other expenses for Q3 FY 13 stands at Rs.131.03 Cr;
compared to Rs.126.60 Cr inQ2 FY 13
(+3.5%); and Rs.114.56 Cr In Q3 FY 12 (+14.38%).
Total expenses for Q3 FY 13 stands at Rs.736.94 Cr;
compared to Rs.719.32 Cr inQ2 FY 13 (+2.45%);
and Rs.620.63Cr In Q3 FY 12 (+18.74%).
Profit before taxfor Q3 FY 13 stands at
Rs.107.56 Cr; compared to Rs.112.53 Cr inQ2 FY 13 (-4.42%); and Rs.91.83 Cr In Q3 FY 12 (+17.13%).
Q3 FY 13 stands at Rs.26.92Cr; compared
to Rs.29.29 Cr inQ2 FY 13 (-8.09%); and
Rs.27.18 Cr In Q3 FY 12 (-0.96%).
Net Profitfor Q3
FY 13 stands at Rs.80.64Cr; compared to Rs.83.24 Cr inQ2 FY 13 (-3.12%); and Rs.64.65 Cr In Q3 FY
12 (+24.73%).The YoY Growth in respect of net Sales and net Profit isimpressive.
Face Valuefor Q3 FY 13 stands at Rs.5 and the Paid-up
Equity stands at Rs.69.56 Cr.
Basic EPSfor Q3
FY 13 stands at Rs.5.8; compared to Rs.6.02 in Q2 FY 13; and Rs.4.89 in Q3 FY
Public holdingin the company is 61.93%.
EXCERPTS FROM THE COMPANY’S RELEASE
Apollo Hospitals announced Q3
FY13 results Strong Quarter with Well-rounded Performance. World’s #1Transplant
Hospital Group with more than 1200 solid organ transplants for the year 2012, Apollo
Specialty Hospital, Chennai successfully completed 500 Bone Marrow Transplants;
Announces Establishment of the first Proton Therapy center for Cancer treatment
consolidated financial resultsfor
the quarter and nine months ended December 31, 2012.
Q3 FY13 ConsolidatedRevenues up 22.2 % at Rs.9,809 million
Consolidated EBITDA up 18.9% at
Consolidated PAT up 22.2% at
Q3 FY13 Standalone Revenuesup 19.7% at Rs.8,558million
Standalone EBITDA up 20.5% at
Standalone PAT up 24.7 % at
Commenting on the performance, Dr. Prathap C Reddy, Chairman
said, “We are pleased to report continued growth and operating improvements in
Q3 driven by sustained focus on clinical excellence. We continue to pioneer the
introduction of technology based treatment in India with our plan to set up the
first ever Proton Therapy Center in the region at Chennai. This new facility
will offer patients across Asia, Africa and Australia the most advanced
radiation therapy technology and enhance Apollo Hospitals’ ability to provide
superior cancer treatment.
He added , “The improving
performance of our pharmacies business is contributing to balanced growth. The
sale of our stake in Apollo Health Street has also strengthened our balance
sheet as we are embarking on a never before expansion plan with 14 hospitals
scheduled to be added to our network over the next 30 months .”
• Standalone Q3FY13 Performance
O Revenues grew 19.7% to Rs.8,558
million compared to Rs.7,148million in Q3 FY12.
O EBITDA grew 20.5% to Rs.1,464
million as against Rs.1,215 million in Q3 FY12.
O PAT was Rs.806 million vs.
Rs.647 million in Q3 FY12, growth of 24.7%.
O Diluted EPS of Rs.5.80 per
share in Q3 FY13 (not annualised)
• Standalone 9M FY13 Performance
O Revenues grew 20.1 % to
Rs.24,695 million compared to Rs.20,555 million in 9M FY12.
O EBITDA grew 22.2 % to Rs. 4,208
million as against Rs.3,444 million in 9M FY12.
O PAT was Rs.2,336 million in 9M FY13
vs. Rs.1,717 million in 9M FY12.
O Diluted EPS of Rs. 16.79 per
share in 9M FY13
• Consolidated Q3 FY13 Performance*#
O Revenues grew 22.2% to Rs.9,809
million compared to Rs.8,029 million in Q3 FY12.
O EBITDA grew 18.9 % to Rs.1,587 million
as against Rs.1,335 million in Q3 FY12.
O PAT was Rs.746 million vs.
Rs.610 million in Q 3 FY12, growth of 22.2%.
O Diluted EPS of Rs.5.36 per
share in Q3 FY13 (not annualised)
• Consolidated 9M FY13 Performance*#
O Revenues grew 22.2% to
Rs.28,242 million compared to Rs.23,111 million in 9M FY12.
O EBITDA grew 22.8% to Rs.4,687 million
as against Rs.3,815 million in 9M FY12.
O PAT was Rs.2,351 million in 9M FY13
vs. Rs.1,741 million in 9M FY12.
O Diluted EPS of Rs.16.90 per
share in 9M FY13
* The Consolidated financials are
unaudited management estimates
# Apollo Health Street financials
have not been considered in the consolidated financials after the Share
Purchase agreement for the divestiture has been signed with Sutherland.
• Standalone Pharmacies continued
to report stellar growth –Q 3 revenues grew 29.3% on a y-on-y basis to Rs.2,905
million – aided by robust same store sales growth, focus on private labels and renewed
momentum in expansion of the pan - India network of stores.
• Apollo Hospitals has signed a
definitive agreement with Sutherland Global Services (SGS) under which SGS will
acquire a 100% stake in Apollo Health Street(AHS). The listed entity, AHEL,
holds a 39% stake in AHS; the balance being held by promoters, Institutional
Investors & Minority Shareholders. The deal is expected to close in Feb 2013
subject to regulatory and other conditions.
• Apollo Hospitals has announced
plans to establish a Proton Therapy Center in Chennai. The center, with an approximate
investment of Rs. 400 crores, is designed with state – of -the-art technology,
Proteus®PLUS from IBA (Ion Beam Applications S.A.) to provide best -in-class
treatment for cancer treatment.
Awards & Achievements
• Apollo Hospitals was voted the
No. 1 private hospital in India (Week–HANSA Best Hospital Survey, 2012).
• Apollo Hospitals bagged the
‘Asia Responsible Entrepreneurship Awards’ (AREA) South Asia 2012 under two
categories organized by Enterprise Asia on 13th December in New Delhi. Group
Chairman, Dr. Prathap Reddy won the prestigious Responsible Business Leader Category
and Billion Hearts Beating Foundation won the praiseworthy Health Promotion Award.
• Indraprastha Apollo Hospitals
won the “Times Research Media Healthcare Excellence Awards 2012” on 26th
December 2012, in three categories - India's most innovative hospital, best
diagnostic and imaging centre in North India and best heart care centre in
About Apollo Hospitals Enterprise Ltd. (AHEL)
It was in 1983, that Dr. Prathap
Reddy made a pioneering endeavour by launching India’s first corporate hospital
- Apollo Hospital in Chennai. Now, as Asia largest and most trusted healthcare
group, its presence includes over 8,020 Beds across 49 Hospitals, 1,445 Pharmacies,
100 primary care and diagnostic Clinics, 100 Telemedicine units across 10 countries
(added Burma in Q3).
Health Insurance services, Global
Projects Consultancy, 15 colleges of Nursing and Hospital Management and a
Research Foundation with a focus on global Clinical Trials, epidemiological
studies, stem cell & genetic research and the first Proton Therapy Center
across Asia, Africa and Australia .
In a rare honor , the Government
of India issued a commemorative stamp in recognition of Apollo's contribution,
the first for a healthcare organization. Apollo Hospitals Chairman, Dr. Prathap
C Reddy, was conferred with the prestigious Padma Vibhushan in 2010. For more
than 30 years, the Apollo Hospitals Group has continuously excelled and maintained
leadership in medical innovation, world - class clinical services and cutting -
edge technology. Our hospitals are consistently ranked amongst the best
hospitals globally for advanced medical services and research.